Differential effects of thymoquinone on lysophosphatidic acid-induced oncogenic pathways in ovarian cancer cells

10.1016/j.jtcme.2020.04.001

Ji Hee Ha；Muralidharan Jayaraman；Rangasudhagar Radhakrishnan；Rohini Gomathinayagam；Mingda Yan；Yong Sang Song；Ciro Isidoro；Danny N. Dhanasekaran

Ovarian cancer ； LPA ； Thymoquinone ； Phytochemical ； Anticancer

Journal of Traditional and Complementary Medicine

10卷3期（2020 / 05 / 01）

207 - 216

英文

Thymoquinone, a therapeutic phytochemical derived from Nigella sativa, has been shown to have a potent anticancer activity. However, it has been identified that the tumor microenvironment (TME) can attenuate the anticancer effects of thymoquinone (TQ) in ovarian cancer. Lysophosphatidic acid (LPA), a lipid growth factor present in high concentration in the TME of ovarian cancer, has been shown to regulate multiple oncogenic pathways in ovarian cancer. Taking account of the crucial role of LPA in the genesis and progression of ovarian cancer, the present study is focused on assessing the efficacy of TQ in inhibiting LPA-stimulated oncogenic pathways in ovarian cancer cells. Our results indicate that TQ is unable to attenuate LPA-stimulated proliferation or metabolic reprogramming in ovarian cancer cells. However, TQ potently inhibits the basal as well as LPA-stimulated migratory responses of the ovarian cancer cells. Furthermore, TQ abrogates the invasive migration of ovarian cancer cells induced by Gαi2, through which LPA stimulates cell migration. TQ also attenuates the activation of JNK, Src, and FAK, the downstream signaling nodes of LPA-LPAR-Gαi2 signaling pathway. In addition to establishing the differential effects of TQ in ovarian cancer cells, our results unravel the antitherapeutic role of LPA in the ovarian cancer TME could override the inhibitory effects of TQ on cell proliferation and metabolic reprogramming of ovarian cancer cells. More importantly, the concomitant finding that TQ could still sustain its inhibitory effect on LPA-stimulated invasive cell migration, points to its potential use as a response-specific therapeutic agent in ovarian cancer.

1. Asaduzzaman Khan, M,Tania, M,Fu, S,Fu, J(2017).Thymoquinone, as an anticancer molecule: from basic research to clinical investigation.Oncotarget,8(31),51907-51919.
2. Banerjee, S,Padhye, S,Azmi, A(2010).Review on molecular and therapeutic potential of thymoquinone in cancer.Nutr Canc,62(7),938-946.
3. Bian, D,Su, S,Mahanivong, C(2004).Lysophosphatidic acid stimulates ovarian cancer cell migration via a ras-MEK kinase 1 pathway.Canc Res.,64(12),4209-4217.
4. Buick, RN,Pullano, R,Trent, JM(1985).Comparative properties of five human ovarian adenocarcinoma cell lines.Canc Res,45(8),3668-3676.
5. Fernandez-de-Cossio-Diaz, J,Vazquez, A(2017).Limits of aerobic metabolism in cancer cells.Sci Rep,7(1),13488.
6. Goldsmith, ZG,Ha, JH,Jayaraman, M,Dhanasekaran, DN(2011).Lysophosphatidic acid stimulates the proliferation of ovarian cancer cells via the gep proto-oncogene galpha(12).Genes Cancer,2(5),563-575.
7. Gomathinayagam, R,Muralidharan, J,Ha, JH,Varadarajalu, L,Dhanasekaran, DN(2014).Hax-1 is required for Rac1-Cortactin interaction and ovarian carcinoma cell migration.Genes Cancer,5(3-4),84-99.
8. Goyal, SN,Prajapati, CP,Gore, PR(2017).Therapeutic potential and pharmaceutical development of thymoquinone: a multitargeted molecule of natural origin.Front Pharmacol,8,656.
9. Ha, JH,Radhakrishnan, R,Jayaraman, M(2018).LPA induces metabolic reprogramming in ovarian cancer via a pseudohypoxic response.Canc Res,78(8),1923-1934.
10. Ha, JH,Ward, JD,Radhakrishnan, R,Jayaraman, M,Song, YS,Dhanasekaran, DN(2016).Lysophosphatidic acid stimulates epithelial to mesenchymal transition marker Slug/Snail2 in ovarian cancer cells via Galphai2, Src, and HIF1alpha signaling nexus.Oncotarget,7(25),37664-37679.
11. Ha, JH,Yan, M,Gomathinayagam, R(2016).Aberrant expression of JNK-associated leucine-zipper protein, JLP, promotes accelerated growth of ovarian cancer.Oncotarget,7(45),72845-72859.
12. Hossen, MJ,Yang, WS,Kim, D,Aravinthan, A,Kim, JH,Cho, JY(2017).Thymoquinone: an IRAK1 inhibitor with in vivo and in vitro anti-inflammatory activities.Sci Rep,7,42995.
13. Huq, F,Yu, JQ,Beale, P(2014).Combinations of platinums and selected phytochemicals as a means of overcoming resistance in ovarian cancer.Anticancer Res,34(1),541-545.
14. Imran, M,Rauf, A,Khan, IA(2018).Thymoquinone: a novel strategy to combat cancer: a review.Biomed Pharmacother,106,390-402.
15. Khan, MA,Tania, M,Fu, J(2019).Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics.Drug Discov Today,24(12),2315-2322.
16. Kolli-Bouhafs, K,Boukhari, A,Abusnina, A(2012).Thymoquinone reduces migration and invasion of human glioblastoma cells associated with FAK, MMP-2 and MMP-9 down-regulation.Invest N Drugs,30(6),2121-2131.
17. Kumar, RN,Ha, JH,Radhakrishnan, R,Dhanasekaran, DN(2006).Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galpha12.Mol Cell Biol,26(1),50-62.
18. Kundu, J,Chun, KS,Aruoma, OI,Kundu, JK(2014).Mechanistic perspectives on cancer chemoprevention/chemotherapeutic effects of thymoquinone.Mutat Res,768,22-34.
19. Lanier, TL,Berger, EK,Eacho, PI(1989).Comparison of 5-bromo-2-deoxyuridine and [3H]thymidine for studies of hepatocellular proliferation in rodents.Carcinogenesis,10(7),1341-1343.
20. Li, F,Rajendran, P,Sethi, G(2010).Thymoquinone inhibits proliferation, induces apoptosis and chemosensitizes human multiple myeloma cells through suppression of signal transducer and activator of transcription 3 activation pathway.Br J Pharmacol,161(3),541-554.
21. Liu, X,Dong, J,Cai, W,Pan, Y,Li, R,Li, B(2017).The effect of thymoquinone on apoptosis of SK-OV-3 ovarian cancer cell by regulation of bcl-2 and bax.Int J Gynecol Canc,27(8),1596-1601.
22. Lunt, SY,Vander Heiden, MG(2011).Aerobic glycolysis: meeting the metabolic requirements of cell proliferation.Annu Rev Cell Dev Biol,27,441-464.
23. Mahmoud, YK,Abdelrazek, HMA(2019).Cancer: thymoquinone antioxidant/prooxidant effect as potential anticancer remedy.Biomed Pharmacother,115,108783.
24. Mostofa, AGM,Hossain, MK,Basak, D,Bin Sayeed, MS(2017).Thymoquinone as a potential adjuvant therapy for cancer treatment: evidence from preclinical studies.Front Pharmacol,8,295.
25. Nessa, MU,Beale, P,Chan, C,Yu, JQ,Huq, F(2011).Synergism from combinations of cisplatin and oxaliplatin with quercetin and thymoquinone in human ovarian tumour models.Anticancer Res,31(11),3789-3797.
26. Park, JE,Kim, DH,Ha, E(2019).Thymoquinone induces apoptosis of human epidermoid carcinoma A431cells through ROS-mediated suppression of STAT3.Chem Biol Interact,312,108799.
27. Radhakrishnan, R,Ha, JH,Jayaraman, M(2019).Ovarian cancer cell-derived lysophosphatidic acid induces glycolytic shift and cancer-associated fibroblast-phenotype in normal and peritumoral fibroblasts.Canc Lett,442,464-474.
28. Radhika, V,Onesime, D,Ha, JH,Dhanasekaran, N(2004).Galpha13 stimulates cell migration through cortactin-interacting protein Hax-1.J Biol Chem,279(47),49406-49413.
29. Selby, PJ,Thomas, JM,Monaghan, P,Sloane, J,Peckham, MJ(1980).Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation.Br J Canc.,41(1),152-61.
30. Shoieb, AM,Elgayyar, M,Dudrick, PS,Bell, JL,Tithof, PK(2003).In vitro inhibition of growth and induction of apoptosis in cancer cell lines by thymoquinone.Int J Oncol.,22(1),107-113.
31. Trang, NT,Wanner, MJ,Phuong le, VN,Koomen, GJ,Dung, NX(1993).Thymoquinone from eupatorium ayapana.Planta Med,59(1),99.
32. Umar, S,Hedaya, O,Singh, AK,Ahmed, S(2015).Thymoquinone inhibits TNF-alpha-induced inflammation and cell adhesion in rheumatoid arthritis synovial fibroblasts by ASK1 regulation.Toxicol Appl Pharmacol,287(3),299-305.
33. Ward, JD,Dhanasekaran, DN(2012).LPA stimulates the phosphorylation of p130Cas via Galphai2 in ovarian cancer cells.Genes Cancer,3(9-10),578-591.
34. Ward, JD,Ha, JH,Jayaraman, M,Dhanasekaran, DN(2015).LPA-mediated migration of ovarian cancer cells involves translocalization of Galphai2 to invadopodia and association with Src and beta-pix.Canc Lett,356(2 Pt B),382-391.
35. Westhoff, MA,Serrels, B,Fincham, VJ,Frame, MC,Carragher, NO(2004).SRC-mediated phosphorylation of focal adhesion kinase couples actin and adhesion dynamics to survival signaling.Mol Cell Biol,24(18),8113-8133.
36. Wilson, AJ,Saskowski, J,Barham, W,Khabele, D,Yull, F(2015).Microenvironmental effects limit efficacy of thymoquinone treatment in a mouse model of ovarian cancer.Mol Canc,14,192.
37. Wilson, AJ,Saskowski, J,Barham, W,Yull, F,Khabele, D(2015).Thymoquinone enhances cisplatin-response through direct tumor effects in a syngeneic mouse model of ovarian cancer.J Ovarian Res,8,46.
38. Woo, CC,Kumar, AP,Sethi, G,Tan, KH(2012).Thymoquinone: potential cure for inflammatory disorders and cancer.Biochem Pharmacol,83(4),443-451.
39. Xu, Y.(2018).Lysophospholipid signaling in the epithelial ovarian cancer tumor microenvironment.Cancers,10(7)
40. Yada, E,Wada, S,Yoshida, S,Sasada, T(2018).Use of patient-derived xenograft mouse models in cancer research and treatment.Future Sci OA,4(3),FSO271.